G Protein News and Research

RSS

European trial casts doubt over the viability of prostate cancer screening

A large European trial has cast doubt over the viability of prostate cancer screening, concluding that one in eight men receive a positive test result when they do not have the disease.

13 Jan 2010

NOVAVAX completes pre-clinical safety and efficacy study of its RSV vaccine candidate

Novavax, Inc. announced today that it has successfully completed a pre-clinical safety and efficacy study of its RSV vaccine candidate in cotton rats. Results from this study are needed to support an Investigational New Drug (IND) application to advance this novel recombinant F protein particle based RSV (RSV-F) vaccine candidate into clinical development. This vaccine candidate is composed of recombinant 'F' or 'fusion' protein of RSV which is used by the virus to infect and fuse with cells in the respiratory tract and cause disease.

13 Jan 2010

Scientists go beyond single-gene models to probe inborn heart defects

Studying genes that regulate early heart development in animals, scientists have solved a puzzle about one gene's role, finding that it acts in concert with a related gene. Their finding contributes to understanding how the earliest stages of heart development may go awry, resulting in congenital heart defects in humans.

12 Jan 2010

Abraxis Bioscience awards John Wayne Cancer Institute $1M grant for identifying new cancer biomarkers

A $1 million grant from Abraxis Bioscience, Inc. to a world-famous research laboratory at John Wayne Cancer Institute at Saint John’s Health Center could help save lives of cancer patients by helping doctors more rapidly assess whether a treatment is working or not.

12 Jan 2010

MedGenesis Therapeutix enters into license agreement with Amgen

MedGenesis Therapeutix Inc. ("MedGenesis"), a biopharmaceutical company developing and commercializing innovative treatments for patients with serious central nervous system (CNS) diseases, announced today that it has successfully entered into an agreement with Amgen Inc. ("Amgen"), granting MedGenesis an exclusive, worldwide license for glial cell line-derived neurotrophic factor (GDNF) protein in CNS and non-CNS indications, subject to the rights of a co-exclusive licensee for CNS indications in certain countries, as further described below.

12 Jan 2010

Curemark retains Rubenstein Public Relations

Curemark, a drug research and development company that focuses on the treatment of neurological diseases, has retained Rubenstein Public Relations to help raise national, regional, and industry awareness of the organization's research, treatments and founder, Dr. Joan Fallon. Curemark is developing an autism treatment that will be one of the first to address the underlying physiology of autism.

12 Jan 2010

Lead even below level "of concern" for children may impair kidney function

Small amounts of lead in the bodies of healthy children and teens — amounts well below the levels defined as "concerning" by the U.S. Centers for Disease Control and Prevention (CDC) — may worsen kidney function, according to a Johns Hopkins Children's Center study published in the Jan. 11 issue of Archives of Internal Medicine.

12 Jan 2010

Stem cell therapy holds promise as potential alternative to bone grafting operations

A study published this week reinforces the potential value of stem cells in repairing major injuries involving the loss of bone structure.

12 Jan 2010

New findings would allow doctors to tailor drug cocktails for particular viral strains

Chemists at UC San Diego and statisticians at Harvard University have developed a novel way to trace mutations in HIV that lead to drug resistance. Their findings, once expanded to the full range of drugs available to treat the infection, would allow doctors to tailor drug cocktails to the particular strains of the virus found in individual patients.

12 Jan 2010

Mind/body techniques could help patients with celiac disease adhere to gluten-free diet

For adults and children diagnosed with celiac disease, the only treatment is a gluten-free diet, which can be very challenging. Gastroenterologists at Rush University Medical Center are conducting a new study to see if mind/body techniques could help patients with celiac disease adhere to the very strict diet.

12 Jan 2010

Protein bits produced by unusual "reading" of HIV genome can induce immune responses

Two new studies showing that protein bits produced by unusual "reading" of the HIV genome can induce immune responses will appear online in the Journal of Experimental Medicine on Jan. 11 (www.jem.org).

12 Jan 2010

Millipore introduces new Viresolve Pro+ Solution

Millipore Corporation, a leading provider of technologies, tools and services for the global life science industry, today announced the availability of its new Viresolve® Pro+ Solution, an innovative virus filtration product that further extends the company’s leadership in the rapidly growing and highly regulated virus safety market.

12 Jan 2010

Pfizer commences recruitment for Phase I clinical trial of SA3Ag vaccine

Inhibitex, Inc. today announced that its collaborator, Pfizer, Inc., has initiated patient recruitment for 408-patient, randomized, double-blind Phase I clinical trial to evaluate the safety, tolerability, and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus (S. aureus) vaccine (SA3Ag) in healthy adults.

12 Jan 2010

AvidBiotics and Ecolab to develop new technology that reduces food pathogens in meat products

AvidBiotics Corp. and Ecolab Inc. today announced an agreement under which they will work to develop a new technology to dramatically reduce the presence of the dangerous pathogen E. coli O157:H7 in red meat products.

12 Jan 2010

PDGFR's role in new blood vessel formation may explain cardiovascular side effects

A growth factor that is a common target of cancer drugs also plays an important role in the heart's response to stress, researchers at The University of Texas M. D. Anderson Cancer Center report online this week in the Journal of Clinical Investigation.

12 Jan 2010

Proteinuria, a long accepted indicator of heart disease risk, has less impact on African-Americans compared to whites

The cardiovascular risk that is associated with proteinuria, or high levels of protein in the urine, a common test used by doctors as an indicator of increased risk for progressive kidney disease, heart attack and stroke, has race-dependent effects, according to a new study by researchers at Wake Forest University School of Medicine.

12 Jan 2010

University of Haifa receives grant to investigate role of protein expression in memory formation

Prof. Kobi Rosenblum, Head of the Department of Neurobiology and Ethology at the University of Haifa, has been awarded a -1.6 million grant from DIP, a German-Israeli Project Cooperation, over a five-year period. This grant will fund Prof. Rosenblum's international research of the role of protein expression in memory formation and stability.

12 Jan 2010

Pfizer commences SBI-087 Phase 2 clinical trial for RA

Trubion Pharmaceuticals, Inc. today announced that its collaboration partner, Pfizer, has initiated a Phase 2 clinical trial of SBI-087 (PF-05230895) for the treatment of rheumatoid arthritis (RA). SBI-087 is a next-generation, humanized Small Modular ImmunoPharmaceutical (SMIP(TM)) protein therapeutic directed against the CD20 antigen. SBI-087 is also being evaluated in Phase 1 clinical trials for RA and systemic lupus erythematosus (SLE).

12 Jan 2010

Cancer drug may provide an effective secondary treatment for gut tumor

A drug that is already an approved therapy for some cancers also might be an effective secondary treatment for a rare tumor of the gastrointestinal tract, according to a team led by researchers from the University of Pittsburgh Cancer Institute (UPCI). The findings, based on experiments using cell cultures, were published in the Jan. 1 issue of Cancer Research.

12 Jan 2010

New therapeutic treatment may provide a potential alternative to bone grafting operation

A study published this week reinforces the potential value of stem cells in repairing major injuries involving the loss of bone structure.

12 Jan 2010

G Protein News and Research

European trial casts doubt over the viability of prostate cancer screening

NOVAVAX completes pre-clinical safety and efficacy study of its RSV vaccine candidate

Scientists go beyond single-gene models to probe inborn heart defects

Abraxis Bioscience awards John Wayne Cancer Institute $1M grant for identifying new cancer biomarkers

MedGenesis Therapeutix enters into license agreement with Amgen

Curemark retains Rubenstein Public Relations

Lead even below level "of concern" for children may impair kidney function

Stem cell therapy holds promise as potential alternative to bone grafting operations

New findings would allow doctors to tailor drug cocktails for particular viral strains

Mind/body techniques could help patients with celiac disease adhere to gluten-free diet

Protein bits produced by unusual "reading" of HIV genome can induce immune responses

Millipore introduces new Viresolve Pro+ Solution

Pfizer commences recruitment for Phase I clinical trial of SA3Ag vaccine

AvidBiotics and Ecolab to develop new technology that reduces food pathogens in meat products

PDGFR's role in new blood vessel formation may explain cardiovascular side effects

Proteinuria, a long accepted indicator of heart disease risk, has less impact on African-Americans compared to whites

University of Haifa receives grant to investigate role of protein expression in memory formation

Pfizer commences SBI-087 Phase 2 clinical trial for RA

Cancer drug may provide an effective secondary treatment for gut tumor

New therapeutic treatment may provide a potential alternative to bone grafting operation

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News